Development of Assays to Measure GNE Gene Potency and Gene Replacement in Skeletal Muscle
BACKGROUND: GNE myopathy (GNEM) is a severe muscle disease caused by mutations in the UDP-GlcNAc-2-epimerase/ManNAc-6-kinase (GNE) gene, which encodes a bifunctional enzyme required for sialic acid (Sia) biosynthesis.
OBJECTIVE: To develop assays to demonstrate the potency of AAV gene therapy vectors in making Sia and to define the dose required for replacement of endogenous mouse Gne gene expression with human GNE in skeletal muscles.
METHODS: A MyoD-inducible Gne-deficient cell line, Lec3MyoDI, and a GNE-deficient human muscle cell line, were made and tested to define the potency of various AAV vectors to increase binding of Sia-specific lectins, including MAA and SNA. qPCR and qRT-PCR methods were used to quantify AAV biodistribution and GNE gene expression after intravenous delivery of AAV vectors designed with different promoters in wild-type mice.
RESULTS: Lec3 cells showed a strong deficit in MAA binding, while GNE-/-MB135 cells did not. Overexpressing GNE in Lec3 and Lec3MyoDI cells by AAV infection stimulated MAA binding in a dose-dependent manner. Use of a constitutive promoter, CMV, showed higher induction of MAA binding than use of muscle-specific promoters (MCK, MHCK7). rAAVrh74.CMV.GNE stimulated human GNE expression in muscles at levels equivalent to endogenous mouse Gne at a dose of 1×1013vg/kg, while AAVs with muscle-specific promoters required higher doses. AAV biodistribution in skeletal muscles trended higher when CMV was used as the promoter, and this correlated with increased sialylation of its viral capsid.
CONCLUSIONS: Lec3 and Lec3MyoDI cells work well to assay the potency of AAV vectors in making Sia. Systemic delivery of rAAVrh74.CMV.GNE can deliver GNE gene replacement to skeletal muscles at doses that do not overwhelm non-muscle tissues, suggesting that AAV vectors that drive constitutive organ expression could be used to treat GNEM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of neuromuscular diseases - 10(2023), 5 vom: 14., Seite 797-812 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zygmunt, Deborah A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AAV |
|---|
| Anmerkungen: |
Date Completed 12.09.2023 Date Revised 18.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3233/JND-221596 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359587194 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359587194 | ||
| 003 | DE-627 | ||
| 005 | 20231226081209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JND-221596 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359587194 | ||
| 035 | |a (NLM)37458043 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zygmunt, Deborah A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of Assays to Measure GNE Gene Potency and Gene Replacement in Skeletal Muscle |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.09.2023 | ||
| 500 | |a Date Revised 18.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: GNE myopathy (GNEM) is a severe muscle disease caused by mutations in the UDP-GlcNAc-2-epimerase/ManNAc-6-kinase (GNE) gene, which encodes a bifunctional enzyme required for sialic acid (Sia) biosynthesis | ||
| 520 | |a OBJECTIVE: To develop assays to demonstrate the potency of AAV gene therapy vectors in making Sia and to define the dose required for replacement of endogenous mouse Gne gene expression with human GNE in skeletal muscles | ||
| 520 | |a METHODS: A MyoD-inducible Gne-deficient cell line, Lec3MyoDI, and a GNE-deficient human muscle cell line, were made and tested to define the potency of various AAV vectors to increase binding of Sia-specific lectins, including MAA and SNA. qPCR and qRT-PCR methods were used to quantify AAV biodistribution and GNE gene expression after intravenous delivery of AAV vectors designed with different promoters in wild-type mice | ||
| 520 | |a RESULTS: Lec3 cells showed a strong deficit in MAA binding, while GNE-/-MB135 cells did not. Overexpressing GNE in Lec3 and Lec3MyoDI cells by AAV infection stimulated MAA binding in a dose-dependent manner. Use of a constitutive promoter, CMV, showed higher induction of MAA binding than use of muscle-specific promoters (MCK, MHCK7). rAAVrh74.CMV.GNE stimulated human GNE expression in muscles at levels equivalent to endogenous mouse Gne at a dose of 1×1013vg/kg, while AAVs with muscle-specific promoters required higher doses. AAV biodistribution in skeletal muscles trended higher when CMV was used as the promoter, and this correlated with increased sialylation of its viral capsid | ||
| 520 | |a CONCLUSIONS: Lec3 and Lec3MyoDI cells work well to assay the potency of AAV vectors in making Sia. Systemic delivery of rAAVrh74.CMV.GNE can deliver GNE gene replacement to skeletal muscles at doses that do not overwhelm non-muscle tissues, suggesting that AAV vectors that drive constitutive organ expression could be used to treat GNEM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AAV | |
| 650 | 4 | |a GNE myopathy | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a muscular dystrophy | |
| 650 | 4 | |a sialic acid | |
| 650 | 7 | |a N-Acetylneuraminic Acid |2 NLM | |
| 650 | 7 | |a GZP2782OP0 |2 NLM | |
| 700 | 1 | |a Lam, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Ashbrook, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Koczwara, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Lek, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Lek, Monkol |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Paul T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuromuscular diseases |d 2014 |g 10(2023), 5 vom: 14., Seite 797-812 |w (DE-627)NLM246466057 |x 2214-3599 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:5 |g day:14 |g pages:797-812 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JND-221596 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 5 |b 14 |h 797-812 | ||